All News

Teclistamab-cqyv shows promising results in treating refractory multiple myeloma, significantly improving survival rates and offering new hope for patients.

Ben Long, MD; and Weston Blakeslee, PhD, discuss how personalized text reminders significantly improve prescription adherence in patients with heart failure and the critical role pharmacists play in reinforcing engagement.

According to the news release, the manufacturers have 30 days to respond.

Jeffery A. Goad, PharmD, MPH, stresses that consistent, evidence-based communication from pharmacists and other health care professionals is essential to maintaining public trust and preventing declines in childhood vaccination.

In October 2025, the FDA approved an updated label update for capecitabine mandating DPYD genetic testing before initiating treatment, unless urgent.

Explore the differences between oral and injectable semaglutide for weight management, focusing on adherence, adverse effects, and patient preferences.

AbbVie partners with the Trump administration to enhance drug affordability and access, committing to significant investments in US pharmaceutical innovation.

Recombinant zoster vaccination against shingles was found to significantly reduce the risk of heart disease and dementia, even after a prior case of shingles.

New research reveals a gut bacteria-derived molecule that enhances lung cancer immunotherapy, potentially improving outcomes for patients with limited treatment options.

Zahra Mahmoudjafari explains how the epcoritamab, rituximab, and lenalidomide regimen delivers durable responses in relapsed or refractory follicular lymphoma while expanding the pharmacist’s role in dosing coordination and toxicity management.

New research uncovers why multiple myeloma affects men more than women, highlighting sex-based differences in disease presentation and risk factors.

The treatment was granted a Prescription Drug User Fee Act target action date of May 10, 2026.

Research reveals how eczema's timing and severity influence children's chances of outgrowing food allergies, highlighting the connection between skin health and allergy tolerance.

Jeffery A. Goad, PharmD, MPH, explains how the shift toward shared clinical decision-making for pediatric vaccines may complicate counseling, reduce vaccine uptake, and increase public health risks.

Subcutaneous copper histidinate injections deliver copper in a form that bypasses the genetic defect caused by Menkes disease.

Pitavastatin shows promise as a novel treatment for triple-negative breast cancer, enhancing chemotherapy efficacy and targeting cancer cell survival pathways.

Dave Berkus’s quip might define the most significant transition in buying and selling medications since the inception of pharmacy benefit managers.

Start 2026 with clear goals, smart planning, and intentional action.

The findings reemphasize a need for mental health support for those in the pharmacy profession.

Explore the potential of GLP-1 agonists in Alzheimer's treatment, their current limitations, and future research directions in neurology.

Pharmacists play a vital role in mental health care, enhancing treatment continuity and bridging gaps between mental and physical health for patients with serious mental illness.

Recently released guidelines enhance chronic kidney disease management, emphasizing early detection and innovative treatments for better patient outcomes.

The FDA approves Naox Link, a groundbreaking in-ear EEG device, transforming brain monitoring and enhancing neurologic care for patients and pharmacists.

Long-term type 2 diabetes significantly increases cardiovascular disease risk, revealing potential biomarkers for early intervention and prevention strategies.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, explains how the epcoritamab, rituximab, and lenalidomide regimen delivers durable responses in relapsed or refractory follicular lymphoma while expanding the pharmacist’s role in dosing coordination and toxicity management.

Explore how pharmacogenomics enhances opioid therapy for effective pain management, optimizing analgesia while minimizing risks of adverse effects.

The pivotal clinical trial supports the concomitant administration of tirzepatide and ixekizumab, which significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

Explore how combining BTK inhibitors with CAR T-cell therapy enhances treatment efficacy for B-cell malignancies while managing potential toxicities.